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Cancer of the colon has an estimated incidence of 31 per 1000 per
year and causes the death of 18.5 per 1000. Adenocarcinoma of the
colon represents 60% of all colorectal cancers diagnosed in
France. 
This document refers to the management of adenocarcinomas of
the colon which account for 90–95% of all large bowel tumours. It
does not consider the more rare tumours such as neuroendocrine
tumours, sarcomas or melanomas. 
These guidelines were validated in April 2000 by the working
group and an update is planned for 2001. 
DIAGNOSIS AND PREOPERATIVE STAGING 
Colonoscopy and biopsy is the only way to make a definitive 
diagnosis of cancer of the colon (standard). A barium enema 
can be used in cases where colonoscopy is difficult (for example 
if the tumour cannot be reached with the colonoscope), to 
localize a small tumour, or to search for synchronous lesions 
(option). 
Preoperative staging must include a complete clinical examina-
tion, appropriate blood tests and an enquiry into the family history.
Chest X-ray and abdominal ultrasound are used for the assessment
of metastatic spread (standard). Analysis of the level of carcino-
embryonic antigen (CAE) is optional; it is has not been clearly
demonstrated that this test affects the therapeutic plan. An abdom-
inal CT scan is useful in the search for metastatic disease in
patients who are obese, if serial imaging is necessary to follow the
disease during treatment and for patients in whom ultrasonography
is difficult. 
CLASSIFICATION 
The standard post-therapeutic classifications (the UICC-AJCC,
Astler-Coller and Dukes classifications) all facilitate subsequent
treatment decisions. The classifications of Gunderson and Sosin
and of the GITSG are options. 
PROGNOSTIC FACTORS 
The standard prognostic factors are the extent of bowel wall infil-
tration, contiguous invasion of adjacent organs, nodal involve-
ment, the number of nodes involved, the number of nodes
removed and the presence of metastases at the time of preoperative
staging. Further studies are necessary to identify or confirm the
value of other prognostic factors. 
TREATMENT MODALITIES 
Surgery 
Preparation for surgery 
The standard bowel preparation includes a thorough bowel
washout with a hypertonic solution combined with a low-residue
diet, an intravenous injection of a broad-spectrum antibiotic and
the marking of planned stoma sites. 
Routine surgical treatment of cancer of the colon 
This comprises the excision of the primary tumour with safe
margins and the excision of vessels and associated mesocolon
containing lymphatic channels and nodes. A median laparotomy
incision is recommended, followed by an examination of the liver,
pelvis and ovaries (in women), with sampling or frozen section of
each suspicious mass. Several procedures can be undertaken
depending on the site of the tumour: hemicolectomy (right or left),
resection of the transverse colon, sigmoidectomy or an anterior
resection of the rectosigmoid. 
Surgical treatment of complex tumours 
There is no standard approach to the surgical treatment of tumours
presenting with bowel obstruction or perforation. It will depend on
the performance status of the patient and the location of the
tumour. If the tumour has invaded neighbouring organs, the resec-
tion should be made ‘en bloc’ (standard). 
A subtotal colectomy is recommended for the treatment of
Lynch syndrome. 
In post-menopausal women, prophylactic bilateral oophorec-
tomy is recommended. Palliative resection of a colon cancer is an
option, depending on the performance status of the patient, the
ease of excision and whether or not the patient is symptomatic. 
Laporoscopic colectomy must not be undertaken outside a
therapeutic trial. 
Bowel anastomosis 
An effective anastomosis requires good bowel preparation. The
vascular supply to adjacent bowel segments must be well main-
tained and should not be subject to undue traction (standard).
Mechanical and manual techniques for anastomosis (staples vs
stitches) give the same results in the hands of experienced
surgeons. In the case of a manual anastomosis, a one-layer anas-
tomosis is recommended. 
Hepatic metastases 
The operability criteria are anatomic (surgery is contra-indicated if
the portal and/or sub-hepatic veins are involved) and technical (the
Carcinoma of the colon 
A Adenis1, T Conroy2, P Lasser3, Y Merrouche4, G Monges5, M Rivoire6, P Rougier7 and S Ruggieri-Pignon5
1Centre Oscar Lambret, Lille; 2Centre Alexis Vautrin, Nancy; 3Institut Gustave Roussy, Villejuif; 4CHRU, Besançon; 5Institut Paoli-Calmettes, Marseille; 6Centre
Léon Bérard, Lyon; 7Hôpital Ambroise Paré, Boulogne, France 
65
British Journal of Cancer (2001) 84 (Supplement 2), 65–68
© 2001 FNCLCC
doi: 10.1054/ bjoc.2001.1767, available online at http://www.idealibrary.com on necessity of leaving more than 30% of normal liver ‘in situ’). It
will also depend on the extent of disease spread (whether or not
there are nodes at the porta hepatis, the presence of non-resectable
metastases outside the liver, the number and size of metastases,
etc) (level of evidence B). Surgery for the excision of hepatic
metastases must result in the removal of all metastases demon-
strated by extensive preoperative scanning. If possible, each
metastasis must be surrounded by a margin of 1 cm of healthy
liver (level of evidence C). The aim is to preserve as much normal
tissue as possible while limiting the amount of blood loss utilizing
hepatic vascular exclusion. The hepatectomy technique is based
on anatomic hepatic segments and depends on the size, the number
and position of the metastases. There is no evidence that hepatec-
tomy gives better results than metastectomy (level of evidence B). 
Radiotherapy 
The role of radiotherapy in the treatment of cancer of the colon has
not been clearly defined. It is an option for the treatment of incom-
pletely excised tumours, especially when the residual tumour is
small and when no other potentially curative therapy is planned. 
Chemotherapy 
Adjuvant chemotherapy 
For stage III colon cancer, adjuvant chemotherapy is standard
(level of evidence A). A 6-month course of combination of 
5-fluorouracil (5-FU) and folinic acid (FA) is standard (level 
of evidence A). The early results of therapeutic trials of post-
operative intraportal chemotherapy are conflicting (level of
evidence C). 
For stage I colon cancers there is no indication for adjuvant
treatment (standard, level of evidence B). The use of adjuvant
chemotherapy for stage II disease remains experimental. 
Palliative chemotherapy 
Chemotherapy is recommended for the palliative treatment of
inoperable cancers of the colon (level of evidence B). Two combi-
nations, 5-FU/FA and 5-FU/methotrexate ± FA (5-FU-MTX ± FA)
are superior in terms of response and toxicity than 5-FU alone
administered by intravenous bolus (level of evidence A). Only
5-FU-MTX ± FA gives a statistically significant increase in
median survival. In a randomized study, the LV 5-FU2 protocol
has been shown to be more effective (in terms of response and
progression-free survival) and less toxic than the Mayo Clinic 5-
FU/FA combination, but without a statistically significant increase
in survival (level of evidence B). 
Continuous infusions of intravenous 5-FU (level of evidence B)
or of raltitrexed (level of evidence C) are options having compar-
able efficacy to the 5-FU/FA combination. 
The addition of oxaliplatin to a 5-FU/FA combination increases
the toxicity and the response rate. The median progression-free
survival is increased by nearly 3 months using oxaliplatin with no
difference in median survival (level of evidence B). The addition
of irinotecan to a 5-FU/FA combination also increases the toxicity
and the response rate, with a 2-month delay in disease progression
and a significant 3-month improvement in overall survival. There
is no difference in quality of life between the two groups (level of
evidence B). The combination of oxaliplatin or irinotecan with 5-
FU/FA as first-line treatment for metastatic disease is optional
(level of evidence B). The value of a triple chronomodulated 
infusion of oxaliplatin, 5-FU and FA has not been established in
that it has not been compared with a standard cytotoxic regimen. 
Hepatic intra-arterial chemotherapy with floxuridine (FUDR) is
an option (level of evidence B) for the treatment of inoperable
hepatic metastases. Its value compared to best systemic treatment
has not been established. 
Immunotherapy 
The efficacy of non-specific immunotherapy and of vaccines has
not been proven. The place of monoclonal antibodies remains to
be confirmed; they should only be used within the framework of
therapeutic trials (option, level of evidence C). 
The management of polyps 
A decision regarding surgery in the management of polyps must be
made on a case-by-case basis by the gastroenterologist, patholo-
gist, surgeon and physician caring for the patient. 
Strict follow-up is necessary after polypectomy. The risk of
subsequently developing a cancer is much greater if the polyp is
villous or tubulovillous and greater than 1 cm in size. For patients
with a non-invasive pedicular or sessile adenomatous polyp of less
than 3 cm in size at the base that has been completely resected
along with any other polyps, a colonoscopy must be performed 3
years after the initial excision. For all other patients, colonoscopy
must be undertaken within a year of the initial excision.
Thereafter, routine surveillance of bowel lesions can be instituted. 
THERAPEUTIC STRATEGY 
Surgery is the main treatment for colon cancer, with the addition of
complimentary or adjuvant treatment as appropriate. 
Adjuvant treatment after curative surgery 
i) There is no indication for additional treatment before obtaining a
complete histological report (standard). Immediate postoperative
chemotherapy with intraportal 5-FU can be given within a thera-
peutic trial (option, level of evidence C) (Figure 1). 
ii) After obtaining a complete histological report: 
Stage I T1 N0 M0 (Dukes A, Astler-Coller A) or T2 N0 M0
(Dukes A, Astler-Coller B1) disease 
There is no indication for adjuvant treatment following resection
(standard) 
Stage II T3 or T4 N0 M0 (Dukes B, Astler-Coller B2) 
There is no indication for adjuvant treatment following resection
(standard). The inclusion of patients within therapeutic trials is
recommended. 
Stage III, any T, NI–3, M0 (Dukes C, Astler-Coller C1 and C2) 
Adjuvant systemic chemotherapy is the standard treatment (level
of evidence A). The combination of 5-FU and FA is standard
(level of evidence A) 
Colon cancer presenting with bowel perforation or
obstruction 
There is no standard therapy. Adjuvant systemic chemotherapy or
the inclusion in a therapeutic trial are options. 
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In metastatic disease, the aim of chemotherapy based on 5-FU is to
improve the duration of survival with maintained or improved
quality of life (Figures 2 and 3). 
It should be given before the appearance of symptoms to
patients with a performance status of 0 1 or 2 who have been fully
informed of the implications of treatment and its side-effects, who
have proven pathology and unresectable metastatic disease.
Standard chemotherapy is a 5-FU-based protocol of low toxicity
(level of evidence B). 
The efficacy of any palliative chemotherapy protocol must be
evaluated after 2–3 months’ treatment. There is no standard for
treatment following a good response to chemotherapy. Surgery (if
possible), or further chemotherapy are options. Chemotherapy
must be discontinued in the face of progressive disease (standard).
Second-line chemotherapy using a different protocol (level of
evidence B) or the inclusion in a therapeutic trial are then options. 
FOLLOW-UP 
The purpose of follow-up after potentially curative surgery for
carcinoma of the colon is to identify a recurrence as early as
possible. The benefit of this is uncertain. No randomized prospec-
tive study has shown an increase in survival or quality of life
following a strategy of surveillance. Follow-up should include a
clinical examination (standard) followed by endoscopy/colonos-
copy (standard). 
Colonoscopy must be undertaken within 12 months of surgery
(6 months if a preoperative colonoscopy was incomplete or not
done) and repeated according to the findings (standard). For Stage
II and III disease (Astler-Coller stage B2 and C), follow-up can be
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Figure 2 Treatment of metastatic colon cancer intensified to identify those patients who are potentially re-oper-
able and combined with an analysis of the level of CEA (option). 
Appropriate imaging includes liver ultrasonography (for
example every 3 months for 2 years, then every 6 months 
for 5 years) plus an annual chest X-ray (option). Prospective
randomized studies must be carried out to evaluate the benefit of
follow-up and to define the best methods, frequency and cost-
effectiveness. 
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Figure 3 Treatment of metastatic colon cancer with unresectable metastases